Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.55 |
| ▸ | DHODH | Q02127 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14969305 | 0.84 | ALDH1A1 (0.57) | ALDH1A1HTTEPHX2DHODHL3MBTL1 | |
| SCHEMBL14969304 | 0.83 | ALDH1A1 (0.56) | ALDH1A1HTTEPHX2DHODHL3MBTL1 | |
| SCHEMBL5901234 | 0.83 | HTT (0.61) | ALDH1A1HTTDHODHL3MBTL1MEN1 | |
| SCHEMBL12269128 | 0.83 | HTR2C (0.55) | HTR2CSLC6A3ALDH1A1HTTEPHX2 | |
| SCHEMBL18995758 | 0.81 | ALDH1A1 (0.60) | ALDH1A1HTTDHODHMEN1KMT2A | |
| SCHEMBL7226538 | 0.80 | ALDH1A1 (0.59) | ALDH1A1HTTEPHX2MEN1KMT2A | |
| SCHEMBL10230989 | 0.80 | ALDH1A1 (0.53) | ALDH1A1HTTEPHX2DHODHMEN1 | |
| SCHEMBL917675 | 0.80 | ALDH1A1 (0.53) | ALDH1A1HTTEPHX2DHODHMEN1 | |
| SCHEMBL8517647 | 0.79 | HTT (0.56) | ALDH1A1HTTL3MBTL1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL9595244 | 0.78 | EPHX2 (0.61) | ALDH1A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376427-B1 | CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUND | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2017-08-02 | — | — | EP | disclosed |
| CN-101896455-B | 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists | THERAVANCE INC | 2015-04-29 | — | — | CN | disclosed |
| CN-101896455-B | 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists | THERAVANCE INC | 2015-04-29 | — | — | CN | disclosed |
| CN-102245564-B | Crystalline forms of a 3-carboxypropyl-aminotetralin compound | THERAVANCE BIOPHARMA R & D IP LLC | 2015-04-01 | — | — | CN | disclosed |
| US-8969370-B2 | 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969370-B2 | 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969370-B2 | 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969367-B2 | Crystalline forms of a 3-carboxypropyl-aminotetralin compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969367-B2 | Crystalline forms of a 3-carboxypropyl-aminotetralin compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140329845-A1 | 3-CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| EP-2231585-A2 | 3-CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AS MU OPIOID RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2010068649-A1 | CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUND | THERAVANCE, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
| US-20100144881-A1 | CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-06-10 | — | — | US | disclosed |
| WO-2009076408-A3 | 3 -CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009076408-A2 | 3 -CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009076408-A2 | 3 -CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20090149535-A1 | 3-CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-06-11 | — | — | US | disclosed |
| US-20090149535-A1 | 3-CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-06-11 | — | — | US | disclosed |
| EP-1200395-A1 | UREA DERIVATIVES AS INHIBITORS OF CCR-3 RECEPTOR | KIRIN BEER KABUSHIKI KAISHA (JP) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001009088-A1 | UREA DERIVATIVES AS INHIBITORS OF CCR-3 RECEPTOR | KIRIN BEER KABUSHIKI KAISHA (JP) | 2001-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149535-A1 | 3-CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRL1, OPRM1, OPRK1 | HTR2C 32/4885SLC6A3 265/4885ALDH1A1 601/4885 |
| US-20140329845-A1 | 3-CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRL1, OPRM1, OPRK1 | HTR2C 32/4885SLC6A3 265/4885ALDH1A1 601/4885 |
| US-20100144881-A1 | CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUND | OPRM1, OPRK1, OPRL1 | HTR2C 14/4885SLC6A3 261/4885ALDH1A1 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.